Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

One could be forgiven for feeling the same way about the current world of drug delivery devices, with an increasingly ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.

Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist to reach the market, but has also benefitted from supply constraints from Novo Nordisk's GLP-1 agonist ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.